Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

JUMP is a phase 3b expanded-access trial for patients without access to ruxolitinib outside of a clinical study; it is the largest clinical trial to date in patients with myelofibrosis who have been treated with ruxolitinib. Here, we present safety and efficacy findings from an analysis of 1144 pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Al-Ali, Haifa Kathrin, Griesshammer, Martin, le Coutre, Philipp, Waller, Cornelius F., Liberati, Anna Marina, Schafhausen, Philippe, Tavares, Renato, Giraldo, Pilar, Foltz, Lynda, Raanani, Pia, Gupta, Vikas, Tannir, Bayane, Ronco, Julian Perez, Ghosh, Jagannath, Martino, Bruno, Vannucchi, Alessandro M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2016
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5060023/
https://ncbi.nlm.nih.gov/pubmed/27247324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.143677
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items